(R1)-(Tetrahydrofuran-2-yl)-5-fluorouracil
CAS: 37076-68-9
Ref. 3D-FT76523
25mg | Ausgelaufen | ||
50mg | Ausgelaufen | ||
100mg | Ausgelaufen | ||
250mg | Ausgelaufen | ||
500mg | Ausgelaufen |
Produktinformation
- Tegafur
- 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, (R)-
- 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-[(2R)-tetrahydro-2-furanyl]-
- 5-Fluoro-1-[(2R)-tetrahydro-2-furanyl]-2,4(1H,3H)-pyrimidinedione
- NSC 200695
- R-1-(Tetrahydrofuran-2-yl)-5-fluorouracil
- Uracil, 5-fluoro-1-(tetrahydro-2-furyl)-, (R)-
- (R)-Ftorafur
(R1)-(Tetrahydrofuran-2-yl)-5-fluorouracil is a prodrug of 5-FU, which is a chemotherapeutic drug used to treat colorectal adenocarcinoma. It is converted in the body to 5-FU by esterases and glucuronidases, which inhibits DNA synthesis and cell division. (R1)-(Tetrahydrofuran-2-yl)-5-fluorouracil has been shown to have anticancer activity in treatment trials with multivariate logistic regression analysis and enzyme activities. The conversion of (R1)-(Tetrahydrofuran-2-yl)-5-fluorouracil into 5-FU can be inhibited by using P450 inhibitors such as ketoconazole and erythromycin, suggesting that this pharmacological agent may not be suitable for patients with liver or renal impairment.